Roswell Park Cancer Institute

/Home/Leukemia Healthcare and Treatment Centers/Leukemia Health Care and Treatment Centers-US/New York Leukemia Healthcare and Treatment Centers

Roswell Park Cancer Institute

Elm & Carlton Streets |
Buffalo, New York 14263 |

1-877-275-7724

Blood Cancers > Leukemia

The Team

Physicians

Minoo Battiwalla, MD
Eunice Wang, MD
Meir Wetzler, MD, - Chief of Leukemia Service

Treatment Options

Roswell Park Cancer Institute Seeking Patients for Clinical Trial With a New Human Anti-CD20 Antibody for Chronic Lymphocytic Leukemia

RPCI is participating in a four center clinical trial in the United States of an investigational drug, called HuMax-CD20 (ofatumumab), for patients with B-cell chronic lymphocytic leukemia (CLL). This study is most appropriate for patients who have not received any treatment for CLL. HuMax-CD20 is a new anti-cancer drug. It is an example of a new generation of antibodies that were developed from human genes (and not from other antibody models that may include human and/or animal genes) and has shown encouraging results in the laboratory and in an international clinical trial. In previous clinical trials, patients receiving HuMax-CD20 experienced fewer side effects, such as fever and shaking chills, than those receiving rituximab. This study will investigate how well it works in conjunction with chemotherapeutic agents that have proven their effectiveness against B-Cell CLL (Fludarabine and Cyclophosphamide). To read the complete press release on this study, click here.

For information about joining this study, contact 1-877-ASK-RPCI (1-877-275-7724).

© Copyright 2009, Roswell Park Cancer Institute